Mineral metabolism abnormalities and vitamin D receptor activation in cardiorenal syndromes

Heart Failure Reviews

Volumn 17, Issue 2, 2012, Pages 211-220

  Ronco, Claudio ^a   Cozzolino, Mario ^b  

^a SAN BORTOLO HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Cardiorenal syndromes; Cardiovascular disease; Chronic kidney disease; Mineral and bone disorder; Vitamin D

Indexed keywords

CALCITRIOL; CALCIUM; PARATHYROID HORMONE; PHOSPHORUS; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; VITAMIN D RECEPTOR;

ARTICLE; CALCIUM BLOOD LEVEL; CARDIORENAL SYNDROME; HORMONE RELEASE; HUMAN; HYPERPARATHYROIDISM; HYPOCALCEMIA; KIDNEY FUNCTION; MINERAL METABOLISM; MORBIDITY; MORTALITY; PHOSPHATE BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

CALCITRIOL; CALCIUM; CARDIO-RENAL SYNDROME; HUMANS; HYPOCALCEMIA; MINERALS; PARATHYROID HORMONE; PHOSPHORUS; RECEPTORS, CALCITRIOL; VITAMIN D;

EID: 84861227721     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-011-9232-8     Document Type: Article

References (70)

1. Ronco C, McCullough PA, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, Hillege H, House AA, Katz N, Maisel A, Mankad S, Zanco P, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ponikowski P (2010) Acute dialysis quality initiative (ADQI) consensus group. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 31:703-711
2. Berl T, Henrich W (2006) Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol 1:8-18
3. Herzog CA (2002) Dismal long-term survival of dialysis patients after acute myocardial infarction: can we alter the outcome? Nephrol Dial Transplant 17:7-10
4. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B (2005) The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J 26:11-17
5. US Renal Data System (2004) USRDS 2004 Annual data report: atlas of end-stage renal disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
6. Hage FG, Venkataraman R, Zoghbi GJ, Perry GJ, DeMattos AM, Iskandrian AE (2009) The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol 53:2129-2140
7. Thomas R, Kanso A, Sedor JR (2008) Chronic kidney disease and its complications. Prim Care 35:329-44, vii
8. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R (2008) Cardiorenal syndrome. J Am Coll Cardiol 52:1527-1539
9. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW (2004) Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 109:1004-1009
10. Breidthardt T, Mebazaa A, Mueller CE (2009) Predicting progression in nondiabetic kidney disease: the importance of cardiorenal interactions. Kidney Int 75:253-255
11. Ronco C, Chionh C-Y, Haapio M, Anavekar NS, House A, Bellomo R (2009) The cardiorenal syndrome. Blood Purif 27: 114-126
12. Ronco C, Cruz DN, Ronco F (2009) Cardiorenal syndromes. Curr Opin Crit Care 15:384-391
13. Geisberg C, Butler J (2006) Addressing the challenges of cardiorenal syndrome. Cleve Clin J Med 73:485-491
14. Bover J, Farré N, Andrés E, Canal C, Olaya MT, Alonso M, Qu?́lez B, Ballar?́n J (2009) Update on the treatment of chronic kidney disease-mineral and bone disorder. J Ren Care 35(Suppl. 1):19-27
15. Smith KR, Smelt SC (2009) Consequences of chronic kidney disease-mineral and bone disorder: a progressive disease. Nephrol Nurs J 36:49-55
16. Vitamin D (2008) Altern Med Rev 13:153-164
17. Ketteler M, Biggar PH (2009) As nature did not predict dialysis-what we can learn from FGF23 in end-stage renal disease? Nephrol Dial Transplant 24:2618-2620
18. Isakova T, Gutiérrez OM, Wolf M (2009) A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney Int 76:705-716
19. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R (2008) Hyperphosphatemia of chronic kidney disease. Kidney Int 74:148-157
20. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL (2007) Prevalence of abnormal serum vitamin D PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71:31-38
21. Alsafwah S, LaGuardia SP, Arroyo M, Dockery BK, Bhattacharya SK, Ahokas RA, Newman KP (2007) Congestive heart failure is a systemic illness: a role for minerals and micronutrients. Clin Med Res 5:238-243
22. Brown AJ, Dusso AS, Slatopolsky E (2002) Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant 17(Suppl. 10):10-19
23. Locatelli F, Cannata-Anda JB, Drüeke TB, Hörl WH, Fouque D, Heimburger O, Ritz E (2002) Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 17:723-731
24. Joy MS, Karagiannis PC, Peyerl FW (2007) Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm 13:397-411
25. Slinin Y, Foley RN, Collins AJ (2005) Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 16:1788-1793
26. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 69:1945-1953
27. Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K (1999) Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 56:1084-1093
28. Nickolas TL, McMahon DJ, Shane E (2006) Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 17:3223-3232
29. Mittalhenkle A, Gillen DL, Stehman-Breen CO (2004) Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis 44:672-679
30. Kaneko TM, Foley RN, Gilbertson DT, Collins AJ (2007) Clinical epidemiology of long-bone fractures in patients receiving hemodialysis. Clin Orthop Relat Res 457:188-193
31. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P (2005) Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68:1815-1824
32. Brancaccio D, Tetta C, Gallieni M, PanichiV(2002) Inflammation, CRP, calcium overload and a high calcium-phosphate product: a 'liaison dangereuse'. Nephrol Dial Transplant 17:201-203
33. Kerr DNS (1997) Hypercalcemia and metastatic calcification. Cardiovasc Res 36:293-297
34. London GM, Guérin AP, Marchais SJ, Métivier F, Pannier B, Adda H (2003) Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18:1731-1740
35. Cozzolino M, Mazzaferro S, Pugliese F, Brancaccio D (2008) Vascular calcification and uremia: what do we know? Am J Nephrol 28:339-346
36. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM (2000) Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87:E10-E17
37. Snijder MB, Lips P, Seidell JC, Visser M, Deeg DJ et al (2007) Vitamin D status and parathyroid hormone levels in relation to blood pressure: a population-based study in older men and women. J Intern Med 261:558-565
38. Zhao G, Ford ES, Li C (2010) Associations of serum concentrations of 25-hydroxyvitamin D and parathyroid hormone with surrogate markers of insulin resistance among US. Adults without physician-diagnosed diabetes: NHANES, 2003-2006. Diabetes Care 33:344-347
39. Fraser A, Williams D, Lawlor DA (2010) Associations of serum 25-hydroxyvitamin D, parathyroid hormone and calcium with cardiovascular risk factors: analysis of 3 NHANES cycles (2001-2006). PLoS One 5(11):e13882
40. Kochupillai N (2008) The physiology of vitamin D: current concepts. Indian J Med Res 127:256-262
41. Nagpal S, Na S, Rathnachalam R (2005) Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 26:662-687
42. Tian J, Liu Y, Williams LA, de Zeeuw D (2007) Potential role of active vitamin D in retarding the progression of chronic kidney disease. Nephrol Dial Transplant 22:321-328
43. Dusso A, Arcidiacono MV, Yang J, Tokumoto M (2010) Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality. J Steroid Biochem Mol Biol 121(1-2):193-198
44. Tishkoff DX, Nibbelink KA, Holmberg KH, Dandu L, Simpson RU (2008) Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology 149:558-564
45. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP (2002) 1, 25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110:229-238
46. Staeva-Vieira TP, Freedman LP (2002) 1, 25-Dihydroxyvitamin D3 inhibits IFN-gamma and IL-4 levels during in vitro polarization of primary murine CD4 + T cells. J Immunol 168:1181-1189
47. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C (2001) Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 86:1633-1637
48. Artaza JN, Mehrotra R, Norris KC (2009) Vitamin D and the cardiovascular system. Clin J Am Soc Nephrol 4:1515-1522
49. Andress D (2007) Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease. Drugs 67:1999-2012
50. Zittermann A, Schleithoff SS, Gotting C, Dronow O, Fuchs U, Kuhn J, Kleesiek K, Tenderich G, Koerfer R (2008) Poor outcome in end-stage heart failure patients with low circulating calcitriol levels. Eur J Heart Fail 10:321-332
51. Giovannucci E, Liu Y, Hollis BW, Rimm EB (2008) 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 168:1174-1180
52. Liu LCY et al (2010) Prognostic value of vitamin D in heart failure. P 5675, ESC 2010 Congress. Eur Heart J 31:1054
53. Mancuso P, Rahman A, Hershey SD, Dandu L, Nibbelink KA, Simpson RU (2008) 1, 25-Dihydroxyvitamin-D3 treatment reduces cardiac hypertrophy and left ventricular diameter in spontaneously hypertensive heart failure-prone (cp/+) rats independent of changes in serum leptin. J Cardiovasc Pharmacol 51(6):559-564
54. Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, Rigor DL, Stillman I, Tamez H, Kroeger PE, Wu-Wong RR, Karumanchi SA, Thadhani R, Kang PM (2007) Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA 104:16810-16815
55. Cozzolino M, Brandenburg V (2009) Paricalcitol and outcome: amanual on how a vitamin D receptor activator (VDRA) can help us to get down the "U". Clin Nephrol 71:593-601
56. Nemerovski CW, Dorsch MP, Simpson RU, Bone HG, Aaronson KD, Bleske BE (2009) Vitamin D and cardiovascular disease. Pharmacotherapy 29:691-708
57. Watson KE, Abrolat ML, Malone LL, Hoeg JM, Doherty T, Detrano R, Demer LL (1997) Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 96:1755-1760
58. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D'Agostino RB, Wolf M, Vasan RS (2008) Vitamin D deficiency and risk of cardiovascular disease. Circulation 117:503-511
59. Melamed ML, Muntner P, Michos ED, Uribarri J, Weber C, Sharma J, Raggi P (2008) Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease: results from NHANES 2001 to 2004. Arterioscler Thromb Vasc Biol 28: 1179-1185
60. Malluche HH, Mawad H, Koszewski NJ (2002) Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure. Kidney Int 62:367-374
61. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R (2006) Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a doubleblind, randomized, placebo-controlled trial. Am J Clin Nutr 83:754-759
62. Baker LR, Abrams L, Roe CJ, Faugere MC, Fanti P, Subayti Y, Malluche HH (1989) 1, 25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial. Kidney Int 35:661-669
63. Wolf M, Thadhani R (2007) Vitamin D in patients with renal failure: a summary of observational mortality studies and steps moving forward. J Steroid Biochem Mol Biol 103:487-490
64. Kooienga L, Fried L, Scragg R, Kendrick J, Smits G, Chonchol M (2009) The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD. Am J Kidney Dis 53(3):408-416
65. Matias PJ, Jorge C, Ferreira C, Borges M, Aires I, Amaral T, Gil C, Cortez J, Ferreira A (2010) Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol 5(5):905-911
66. Jean G, Souberbielle JC, Chazot C (2009) Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant 24(12):3799-3805
67. Marchais SJ, Metivier F, Guerin AP, London GM (1999) Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. Nephrol Dial Transplant 14: 2178-2183
68. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D (2003) Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63:1483-1490
69. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D (2010) Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376(9752):1543-1551
70. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446-456